Choosing among renin-angiotensin system blockers for the management of hypertension: From pharmacology to clinical efficacy

Current Medical Research and Opinion

Volumn 26, Issue 1, 2010, Pages 213-222

  Neutel, J M ^a  

^a Orange County Research Center   (United States)

Author keywords

ACE inhibitor; Angiotensin receptor blocker; Antihypertensive; Blood pressure; Hypertension

Indexed keywords

AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROCHLOROTHIAZIDE; LISINOPRIL; LOSARTAN; OLMESARTAN; PLACEBO; RAMIPRIL; TELMISARTAN; VALSARTAN; ANGIOTENSIN 1 RECEPTOR ANTAGONIST;

ANGIONEUROTIC EDEMA; BLOOD PRESSURE MONITORING; BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; DIZZINESS; DRUG COST; DRUG EFFICACY; DRUG MECHANISM; DRUG TOLERABILITY; FATIGUE; HEADACHE; HEART FAILURE; HUMAN; HYPERTENSION; MEDICAL LITERATURE; MEDICAL PRACTICE; PHARMACOECONOMICS; POPULATION RESEARCH; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SCREENING TEST; TREATMENT DURATION; CARDIOVASCULAR SYSTEM; DRUG EFFECT;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CARDIOVASCULAR SYSTEM; ECONOMICS, PHARMACEUTICAL; HUMANS; HYPERTENSION; RENIN-ANGIOTENSIN SYSTEM;

EID: 77649225373     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007990903444434     Document Type: Review

References (94)

1. Weycker D, Edelsberg J, Vincze G, et al. Blood pressure control in patients initiating antihypertensive therapy. Ann Pharmacother 2008;42:169-76 (Pubitemid 351238563)
2. Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. JAMA 2003;289:2560-72 (Pubitemid 37430158)
3. Kotseva K, Wood D, De Backer G, et al. EUROASPIRE III: a survey on the lifestyle, risk factors and use of cardioprotective drug therapies in coronary patients from 22 European countries. Eur J Cardiovasc Prev Rehabil 2009; 16:121-37
4. Stafford RS, Monti V, Furberg CD, Ma J. Long-term and short-term changes in antihypertensive prescribing by office-based physicians in the United States. Hypertension 2006;48:213-18 (Pubitemid 44309814)
5. Weiss R, Buckley K, Clifford T. Changing patterns of initial drug therapy for the treatment of hypertension in a Medicaid population, 2001-2005. J Clin Hypertens (Greenwich) 2006;8:706-12
6. Mancia G, De Backer G, Dominiczak A, et al. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007;25:1105-87
7. Ubel PA, Jepson C, Asch DA. Misperceptions about beta-blockers and diuretics: a national survey of primary care physicians. J Gen Intern Med 2003; 18:977-83 (Pubitemid 38091391)
8. Fischer MA, Avorn J. Economic implications of evidence-based prescribing for hypertension: can better care cost less? JAMA 2004;291:1850-6 (Pubitemid 38509497)
9. The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992;327:685-91
10. Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin- convertingenzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000;342:145-53
11. The EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003;362:782-8
12. Dagenais GR, Pogue J, Fox K, et al. Angiotensin-converting-enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: a combined analysis of three trials. Lancet 2006;368:581-8 (Pubitemid 44209181)
13. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ 2009;338:b1665
14. Smith DH. Comparison of angiotensin II type 1 receptor antagonists in the treatment of essential hypertension. Drugs 2008;68:1207-25 (Pubitemid 351822111)
15. Heran BS, Wong MM, Heran IK, et al. Blood pressure lowering efficacy of angiotensin receptor blockers for primary hypertension. Cochrane Database Syst Rev 2008;(4):CD003822
16. Carson P, Giles T, Higginbotham M, et al. Angiotensin receptor blockers: evidence for preserving target organs. Clin Cardiol 2001;24:183-90 (Pubitemid 32187063)
17. Israili ZH. Clinical pharmacokinetics of angiotensin II (AT1) receptor blockers in hypertension. J Hum Hypertens 2000;14:S73-86 (Pubitemid 30409970)
18. Mazzolai L, Burnier M. Comparative safety and tolerability of angiotensin II receptor antagonists. Drug Saf 1999;21:23-33 (Pubitemid 29355511)
19. Neutel J, Smith DH. Evaluation of angiotensin II receptor blockers for 24-hour blood pressure control: meta-analysis of a clinical database. J Clin Hypertens 2003;5:58-63
20. Conlin PR, Gerth WC, Fox J, et al. Four-year persistence patterns among patients initiating therapy with the angiotensin II receptor antagonist losartan versus other artihypertensive drug classes. Clin Ther 2001;23: 1999-2010 (Pubitemid 34073191)
21. Vrijens B, Vincze G, Kristanto P, et al. Adherence to prescribed antihypertensive drug treatments: longitudinal study of electronically compiled dosing histories. BMJ 2008;336:1114-17 (Pubitemid 351731741)
22. Lewanczuk R, Tobe SW. More medications, fewer pills: combination medications for the treatment of hypertension. Can J Cardiol 2007;23: 573-6 (Pubitemid 46977993)
23. Dezii CM. A retrospective study of persistence with single-pill combination therapy vs. concurrent two-pill therapy in patients with hypertension. Manag Care 2000;9:2-6
24. Bangalore S, Kamalakkannan G, Parkar S, et al. Fixed-dose combinations improve medication compliance: a meta-analysis. Am J Med 2007;120: 713-19 (Pubitemid 47176510)
25. Elliott WJ, Plauschinat CA, Skrepnek GH, et al. Persistence, adherence, and risk of discontinuation associated with commonly prescribed antihypertensive drug monotherapies. J Am Board Fam Med 2007;20:72-80 (Pubitemid 46219403)
26. Corrao G, Zambon A, Parodi A, et al. Discontinuation of and changes in drug therapy for hypertension among newly-treated patients: a population-based study in Italy. J Hypertens 2008;26:819-24 (Pubitemid 351354932)
27. Patel BV, Remigio-Baker RA, Mehta D, et al. Effects of initial antihypertensive drug class on patient persistence and compliance in a usual-care setting in the United States. J Clin Hypertens (Greenwich) 2007; 9:692-700
28. Burke TA, Sturkenboom MC, Lu SE, et al. Discontinuation of antihypertensive drugs among newly diagnosed hypertensive patients in UK general practice. J Hypertens 2006;24:1193-200 (Pubitemid 43772328)
29. Israili ZH, Hall WD. Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy. A review of the literature and pathophysiology. Ann Intern Med 1992;117:234-42
30. Dykewicz MS. Cough and angioedema from angiotensin-converting enzyme inhibitors: new insights into mechanisms and management. Curr Opin Allergy Clin Immunol 2004;4:267-70 (Pubitemid 39006840)
31. Dicpinigaitis PV. Angiotensin-converting enzyme inhibitor-induced cough: ACCP evidence-based clinical practice guidelines. Chest 2006;129:169-73S
32. Semple PF. Putative mechanisms of cough after treatment with angiotensin converting enzyme inhibitors. J Hypertens 1995;13:S17-21
33. Miller DR, Oliveria SA, Berlowitz DR, et al. Angioedema incidence in US veterans initiating angiotensin-converting enzyme inhibitors. Hypertension 2008;51:1624-30
34. Weber MA, Messerli FH. Angiotensin-converting enzyme inhibitors and angioedema: estimating the risk. Hypertension 2008;51:1465-7
35. Nussberger J, Cugno M, Cicardi M. Bradykinin-mediated angioedema. N Engl J Med 2002;347:621-2
36. Banerji A, Clark S, Blanda M, et al. Multicenter study of patients with angiotensin-converting enzyme inhibitor-induced angioedema who present to the emergency department. Ann Allergy Asthma Immunol 2008;100: 327-32 (Pubitemid 351520323)
37. Reid M, Euerle B, Bollinger M. Angioedema. Available at: http://emedicine. medscape.com/article/135208-overview. [Last accessed 8 June 2009]
38. Irons BK, Kumar A. Valsartan-induced angioedema. Ann Pharmacother 2003; 37:1024-7 (Pubitemid 36875233)
39. Law MR, Wald NJ, Morris JK, et al. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. BMJ 2003;326:1427
40. Howes LG, Tran D. Can angiotensin receptor antagonists be used safely in patients with previous ACE inhibitor-induced angioedema? Drug Saf 2002; 25:73-6 (Pubitemid 34261182)
41. Abdi R, Dong VM, Lee CJ, et al. Angiotensin II receptor blocker-associated angioedema: on the heels of ACE inhibitor angioedema. Pharmacotherapy 2002;22:1173-5 (Pubitemid 34969071)
42. Cicardi M, Zingale LC, Bergamaschini L, et al. Angioedema associated with angiotensin-converting enzyme inhibitor use: outcome after switching to a different treatment. Arch Intern Med 2004;164:910-13 (Pubitemid 38520634)
43. Conlin PR. Angiotensin II antagonists in the treatment of hypertension: more similarities than differences. J Clin Hypertens 2000;2:253-7
44. Kassler-Taub K, Littlejohn T, Elliott W, et al. Comparative efficacy of two angiotensin II receptor antagonists, irbesartan and losartan in mildto- moderate hypertension. Am J Hypertens 1998;11:445-53 (Pubitemid 28231457)
45. Oparil S, Guthrie R, Lewin AJ, et al. An elective-titration study of the comparative effectiveness of two angiotensin II-receptor blockers, irbesartan and losartan. Clin Ther 1998;20:398-409 (Pubitemid 28343494)
46. Gradman AH, Lewin A, Bowling BT, et al. Comparative effects of candesartan cilexetil and losartan in patients with systemic hypertension. Heart Dis 1999; 1:52-7
47. Mallion JM, Siché JP, Lacourcière Y, the Telmisartan Blood Pressure Monitoring Group. ABPM comparison of the antihypertensive profiles of the selective angiotensin II receptor antagonists telmisartan and losartan in patients with mild-to-moderate hypertension. J Hum Hypertens 1999;13: 657-64 (Pubitemid 29481484)
48. Smith DH, Cramer MJ, Neutel JM, et al. Comparison of telmisartan versus losartan: meta-analysis of titration-to-response studies. Blood Press Monit 2003;8:111-17 (Pubitemid 37034566)
49. Zhu JR, Bai J, Cai NS, et al. Efficacy and safety of telmisartan vs. losartan in control of mild-to-moderate hypertension: a multicentre, randomised, double-blind study. Int J Clin Pract Suppl 2004;58:46-9 (Pubitemid 39627047)
50. Lee YT, Lee CM, Lin CS, et al. A double-blind comparison of the efficacy and tolerability of telmisartan 40-80 mg vs. losartan 50-100 mg in Taiwanese hypertensive patients. Int J Clin Pract Suppl 2004;58:40-5
51. White WB, Lacourcière Y, Davidai G. Effects of the angiotensin II receptor blockers telmisartan versus valsartan on the circadian variation of blood pressure: impact on the early morning period. Am J Hypertens 2004;17:347-53 (Pubitemid 38446850)
52. Lacourciere Y, Krzesinski JM, White WB, et al. Sustained antihypertensive activity of telmisartan compared with valsartan. Blood Press Monit 2004;9: 203-10 (Pubitemid 39159163)
53. Littlejohn T, Mroczek W, Marbury T, et al. A prospective, randomized, open-label trial comparing telmisartan 80 mg and valsartan 80 mg in patients with mild-to-moderate hypertension using ambulatory blood pressure monitoring. Can J Cardiol 2000;16:1123-32
54. Bakris G. Comparison of telmisartan vs. valsartan in the treatment of mild to moderate hypertension using ambulatory blood pressure monitoring. J Clin Hypertens 2002;4:26-31
55. Matchar DB, McCrory DC, Orlando LA, et al. Systematic review: comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers for treating essential hypertension. Ann Intern Med 2008; 148:16-29 (Pubitemid 351664943)
56. Williams B, Lacourciere Y, Schumacher H, et al. Antihypertensive efficacy of telmisartan vs ramipril over the 24-h dosing period, including the critical early morning hours: a pooled analysis of the PRISMA I and II randomized trials. J Hum Hypertens 2009;23:610-19
57. Wald DS, Law M, Morris JK, et al. Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials. Am J Med 2009;122:290-300
58. Bobrie G, Delonca J, Moulin C, et al. A home blood pressure monitoring study comparing the antihypertensive efficacy of two angiotensin II receptor antagonist fixed combinations. Am J Hypertens 2005;18:1482-8 (Pubitemid 41566680)
59. Ohma KP, Milon H, Valnes K. Efficacy and tolerability of a combination tablet of candesartan cilexetil and hydrochlorothiazide in insufficiently controlled primary hypertension-comparison with a combination of losartan and hydrochlorothiazide. Blood Press 2000;9:214-20
60. Fogari R, Zoppi A, Mugellini A, et al. Effectiveness of hydrochlorothiazide in combination with telmisartan and olmesartan in adults with moderate hypertension not controlled with monotherapy: a prospective, randomized, open-label, blinded end point (PROBE), parallel-arm study. Curr Ther Res Clin Exp 2008;69:1-15 (Pubitemid 351446018)
61. Neutel JM, Littlejohn TW, Chrysant SGSA, on behalf of the Telmisartan Study Group. Telmisartan/hydrochlorothiazide in comparison with losartan/hydrochlorothiazide in managing patients with mild-to-moderate hypertension. Hypertens Res 2005;28:555-63 (Pubitemid 41387285)
62. Lacourciere Y, Gil-Extremera B, Mueller O, et al. Efficacy and tolerability of fixed-dose combinations of telmisartan plus HCTZ compared with losartan plus HCTZ in patients with essential hypertension. Int J Clin Pract 2003; 57:273-9 (Pubitemid 36700710)
63. Sharma AM, Davidson J, Koval S, et al. Telmisartan/hydrochlorothiazide versus valsartan/hydrochlorothiazide in obese hypertensive patients with type 2 diabetes: the SMOOTH study. Cardiovasc Diabetol 2007;6:28
64. White WB, Davidai G, Schumacher H. Impact of angiotensin receptor blockade in combination with hydrochlorothiazide 25 mg in 2121 patients with stage 1-2 hypertension. J Hum Hypertens epub ahead of print, April 2009; doi: 10.1038/jhh.2009.28
65. Barrios V, Brommer P, Haag U, et al. Olmesartan medoxomil plus amlodipine increases efficacy in patients with moderate-to-severe hypertension after monotherapy: a randomized, double-blind, parallel-group, multicentre study. Clin Drug Investig 2009;29:427-39
66. Littlejohn III TW, Majul CR, Olvera R, et al. Results of treatment with telmisartan- amlodipine in hypertensive patients. J Clin Hypertens (Greenwich) 2009;11:207-13
67. Littlejohn III TW, Majul CR, Olvera R, et al. Telmisartan plus amlodipine in patients with moderate or severe hypertension: results from a subgroup analysis of a randomized, placebo-controlled, parallel-group, 4 x 4 factorial study. Postgrad Med 2009;121:5-14
68. Chrysant SG, Melino M, Karki S, et al. The combination of olmesartan medoxomil and amlodipine besylate in controlling high blood pressure: COACH, a randomized, double-blind, placebo-controlled, 8-week factorial efficacy and safety study. Clin Ther 2008;30:587-604 (Pubitemid 351680489)
69. Philipp T, Smith TR, Glazer R, et al. Two multicenter, 8-week, randomized, double-blind, placebo-controlled, parallel-group studies evaluating the efficacy and tolerability of amlodipine and valsartan in combination and as monotherapy in adult patients with mild to moderate essential hypertension. Clin Ther 2007;29:563-80 (Pubitemid 47028551)
70. Kostis JB. Antihypertensive therapy with CCB/ARB combination in older individuals: focus on amlodipine/valsartan combination. Am J Ther 2009; [Epub ahead of print] doi: 10.1097/MJT.0b013e3181a2ba2d
71. Schrader J, Salvetti A, Calvo C, et al. The combination of amlodipine/valsartan 5/160 mg produces less peripheral oedema than amlodipine 10 mg in hypertensive patients not adequately controlled with amlodipine 5 mg. Int J Clin Pract 2009;63:217-25
72. Schumacher H, Mancia G. The safety profile of telmisartan as monotherapy or combined with hydrochlorothiazide: a retrospective analysis of 50 studies. Blood Press Suppl 2008;1:32-40
73. Gosse P, Schumacher H. Early morning blood pressure surge. J Clin Hypertens (Greenwich) 2006;8:584-9
74. White WB. Importance of blood pressure control over a 24-hour period. J Manag Care Pharm 2007;13:34-9
75. Battershill AJ, Scott LJ. Telmisartan: a review of its use in the management of hypertension. Drugs 2006;66:51-83 (Pubitemid 43148989)
76. Kakuta H, Sudoh K, Sasamata M, et al. Telmisartan has the strongest binding affinity to angiotensin II type 1 receptor: comparison with other angiotensin II type 1 receptor blockers. Int J Clin Pharmacol Res 2005; 25:41-6 (Pubitemid 40571342)
77. Gosse P, Neutel JM, Schumacher H, et al. The effect of telmisartan and ramipril on early morning blood pressure surge: a pooled analysis of two randomized clinical trials. Blood Press Monit 2007;12:141-7 (Pubitemid 46745221)
78. Smith DH, Dubiel R, Jones M. Use of 24-hour ambulatory blood pressure monitoring to assess antihypertensive efficacy: a comparison of olmesartan medoxomil, losartan potassium, valsartan, and irbesartan. Am J Cardiovasc Drugs 2005;5:41-50
79. Oparil S, Williams D, Chrysant SG, et al. Comparative efficacy of olmesartan, losartan, valsartan, and irbesartan in the control of essential hypertension. J Clin Hypertens (Greenwich) 2001;3:283-91, 318
80. Hermida RC, Ayala DE, Khder Y, et al. Ambulatory blood pressure-lowering effects of valsartan and enalapril after a missed dose in previously untreated patients with hypertension: a prospective, randomized, open-label, blinded end-point trial. Clin Ther 2008;30:108-20 (Pubitemid 351834726)
81. Mancia G, Dell'Oro R, Turri C, et al. Comparison of angiotensin II receptor blockers: impact of missed doses of candesartan cilexetil and losartan in systemic hypertension. Am J Cardiol 1999;84:28-34S
82. Lacourciere Y, Asmar R. A comparison of the efficacy and duration of action of candesartan cilexetil and losartan as assessed by clinic and ambulatory blood pressure after a missed dose, in truly hypertensive patients: a placebocontrolled, forced titration study. Candesartan/Losartan study investigators. Am J Hypertens 1999;12:1181-7 (Pubitemid 30029280)
83. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993;342:821-8
84. Bakris G, Burgess E, Weir M, et al. Telmisartan is more effective than losartan in reducing proteinuria in patients with diabetic nephropathy. Kidney Int 2008;74:364-9 (Pubitemid 352002795)
85. Galle J, Schwedhelm E, Pinnetti S, et al. Antiproteinuric effects of angiotensin receptor blockers: telmisartan versus valsartan in hypertensive patients with type 2 diabetes mellitus and overt nephropathy. Nephrol Dial Transplant 2008;23:3174-83
86. Cohn JN, Tognoni G, for the Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001;345:1667-75 (Pubitemid 33126822)
87. Pfeffer MA, Swedberg K, Granger CB, et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 2003;362:759-66 (Pubitemid 37093915)
88. Pfeffer MA, McMurray JJ, Velazquez EJ, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003;349:1893-906 (Pubitemid 37409706)
89. Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359:995-1003 (Pubitemid 34286536)
90. Julius S, Kjeldsen SE, Weber M, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004;363:2022-31 (Pubitemid 38781102)
91. Yusuf S, Teo KK, Pogue J, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008;358:1547-59 (Pubitemid 351522739)
92. Hughes D, McGuire A. The direct costs to the NHS of discontinuing and switching prescriptions for hypertension. J Hum Hypertens 1998;12: 533-7 (Pubitemid 28430222)
93. Paramore LC, Halpern MT, Lapuerta P, et al. Impact of poorly controlled hypertension on healthcare resource utilization and cost. Am J Manag Care 2001;7:389-98 (Pubitemid 32321923)
94. Richter A, Gondek K, Ostrowski C, et al. Mild-to-moderate uncomplicated hypertension: further analysis of a cost-effectiveness study of five drugs. Manag Care Interface 2001;14:61-9